<DOC>
	<DOC>NCT00683267</DOC>
	<brief_summary>Evaluate the efficacy, safety and tolerability of a single intraoperative dose of 4975 in patients undergoing total hip replacement</brief_summary>
	<brief_title>Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement</brief_title>
	<detailed_description>The purpose of this study is to evaluate the efficacy, safety, and tolerability of a single intraoperative dose of 4975 in patients undergoing primary unilateral total hip arthroplasty</detailed_description>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>Key Male or female aged 18 to 85 years with an American Society of Anesthesiologists (ASA) status of I, II, III Planning to undergo unilateral THA In good health and capable of undergoing THA with spinal block and sedation anesthesia No additional planned surgeries during the course of the trial Willing and able to complete the study procedures and pain scales and to communicate meaningfully in English Key A body mass index greater than 40 Known bleeding disorder or is taking agents affecting coagulation preoperatively A medical condition that could adversely impact the patient's participation, safety, or conduct of the study Diabetes mellitus with a known HbA1C&gt;9.5 or a history of prolonged uncontrolled diabetes Previous hip arthroplasty of the same hip Participated in another clinical trial within 30 days of the planned hip surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>THA, Total hip arthroplasty, total hip replacement</keyword>
</DOC>